0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Viewpoint |

Reforming the Payment System for Medical Oncology

Peter B. Bach, MD, MAPP1
[+] Author Affiliations
1Memorial Sloan-Kettering Cancer Center, New York, New York
JAMA. 2013;310(3):261-262. doi:10.1001/jama.2013.8127.
Text Size: A A A
Published online

Extract

Infusion of chemotherapy has long been a profit center for medical oncologists. Under the current system, oncologists purchase cancer drugs at one price, then bill insurers at a higher price after they administer the drugs. However, the profits available to oncologists from this practice have been under serious pressure from the pharmaceutical industry and insurers. Pharmaceutical companies have rapidly increased drug prices while insurers, including the Medicare program, have systematically decreased the reimbursement they provide above the cost of the drug. Even though rising drug prices mean, in general, larger absolute profits to oncologists when they administer more expensive drugs (because the amount of profit is proportional to the purchase price of the drug), the decline in profit margins has made running oncology practices more financially challenging. Increases in drug prices mean increasing costs of inventory, and the resulting lower margins mean less financial flexibility when patients or insurers do not pay their bills on time or in total.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Letters

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 2

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
Paclitaxel and trastuzumab for breast cancer. Hosp Pharm 2014;49(4):338-44.
Gemcitabine and Vinorelbine (GemVin) Regimen. Hosp Pharm 2014;49(6):508-16.
Jobs
brightcove.createExperiences();